Search Job Title Only
Treasury & Bonds
View Full List
Dow Jones Industrial Average
Standard & Poors 500
NYSE COMPOSITE INDX
December 10, 2012 at 13:28 PM EST
Piper Jaffray Reiterates Neutral Rating, $10 PT on ISIS Pharmaceuticals
In a report published Monday, Piper Jaffray & Co. reiterated its Neutral rating and $10.00 price target on ISIS Pharmaceuticals (NASDAQ: ISIS ). Piper Jaffray noted, “This morning, ISIS signed a new antisense collaboration with Biogen Idec (BIIB) for 3 undisclosed neurological and neuromuscular targets. Although the deal brings in
Read More >>
Isis Pharmaceuticals, Inc.
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Terms and Conditions
Press Release Service
provided by PRConnect.
Stock quotes supplied by Six Financial
Bots go here